Allergic Conjunctivitis Model

Study Purpose

Evaluate the efficacy and safety of pharmaceuticals designed to treat allergic conjunctivitis

Type of Model

Induction of allergic conjunctivitis


1-14 days to establish model

Test System

New Zealand White rabbit, guinea pig, rat, or mouse
Animals are prescreened for ocular abnormalities


  • Ophthalmic exams using the McDonald-Shadduck scoring system
  • Quantitative and qualitative in-life imaging techniques including slit-lamp biomicroscopy and ophthalmoscopy
  • Comparison of the test article to currently approved therapeutics
  • Tissue excision and histopathological analysis (optional)
  • Bioanalysis of analyte concentrations in target tissues (optional)

Model Description

  • Animal models are induced by one of the following methods:
    • Parenteral dose of ovalbumin followed by repeated topical dosing of ovalbumin
    • Topical application of compound 48/80
    • Foot pad injection of ragweed pollen followed by repeated topical dosing of ragweed pollen
  • Each model is assessed by the McDonald-Shadduck scoring system
  • Following induction, subjects may be treated with a test compound and currently marketed therapeutic agent as a positive control


  • More accurate classification of the test article’s treatment due to treated and untreated control groups
  • Consistent scoring of the eyes using FDA-required techniques
  • Models are easily reproducible
  • Advanced imaging equipment and expertise in-house to perform all evaluations on-site